Log In
BCIQ
Print this Print this
 

Autologous T regulatory cells (CLBS03) (formerly NBS-03, NBS03D)

  Manage Alerts
Collapse Summary General Information
Company Caladrius Biosciences Inc.
DescriptionPolyclonal T regulatory cell therapy
Molecular Target
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat recent onset type 1 diabetes mellitus; Treat recent-onset Type I diabetes; Treat Type I diabetes; Treat Type I diabetes mellitus with residual beta cell function
Regulatory Designation U.S. - Fast Track (Treat recent-onset Type I diabetes);
U.S. - Orphan Drug (Treat Type I diabetes mellitus with residual beta cell function)
PartnerBecton Dickinson and Co.;
Sanford Health

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today